An observational study in Helicobacter Pylori Infection, Colorectal Cancer and Gastric Cancer, sponsored by University of Latvia. Not yet recruiting. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by University of Latvia · Observational
The EUGastScreen study is designed as a quality implementation study to explore gastric cancer screening strategies within organised cancer screening frameworks. The study is set to target individuals who are entering the age range for CRC screening, integrating gastric cancer screening into this existing structure.
5,734 studies on the registry are indexed under Colorectal Neoplasms; 1,481 are open to participants now.
This study's planned enrollment of 8,000 is above the median of 250 across 1,253 observational studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →University of Latvia is the lead sponsor of 8 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
National healthcare screening databases will be utilized for selecting study participants. The study population will generally be selected from a pre-defined geographical area to ensure access to necessary study facilities. The following regions have been identified as initial study centres:
Original pilot sites Estonia - Tallinn city and Harjumaa municipality; Italy (Marche) - Marche Region - Macerata District; Latvia - Riga city, Jēkabpils region and Aizkraukle, Madona, Varakļāni, Līvāni municipalities; Portugal - North of Portugal, Santo Tirso (Medio Ave Local Health Unit; Barcelos-Esposende Local Health Unit).
Additional pilot sites Italy (Bologna) - Emilia-Romagna Region - Bologna District; Lithuania - Vilnius city municipality.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects eligible for participation in national colorectal cancer screening programme
Diagnostic Test: Fecal sample acquisition for Helicobacter pylori stool antigen test · Diagnostic Test: Upper endoscopy with biopsies · Diagnostic Test: Colonoscopy with biopsies after bowel cleansing · Drug: Helicobacter pylori eradication therapy · Diagnostic Test: Fecal sample acquisition for Fecal Immunochemical test · Diagnostic Test: Breath sample acquisition for 13C Urea Breath Test
Participants will be offered to perform Helicobacter pylori (H. pylori) Stool antigen test (SAT) for H. pylori infection identification. SAT may be used after eradication therapy to confirm H. pylori eradication success instead of 13C Urea Breath Test.
Upper endoscopy will be offered to participants with positive family history and/or alarm symptoms if such are identified (SAT and FIT negative individuals may not undergo questioning for the presence of alarm symptoms), provided a quality-assured endoscopic procedure has not been performed recently.
Colonoscopy will be offered to participants with positive FIT results, or positive family history, provided a quality-assured endoscopic procedure has not been performed recently; or such participants will be managed within national CRC screening programme.
Helicobacter pylori eradication (antimicrobial) therapy offered to participants with Stool antigen test positive results. The recommended approach for first line treatment is bismuth quadruple therapy for 10-14 days, combined with a high-dose PPI BID. The recommended second line eradication medication: Levofloxacin-based quadruple/triple for 14 days plus high-dose PPI BID.
Participants will be offered Fecal Immunochemical test for colorectal cancer screening.
13C Urea Breath test will be offered to participants at least 4 weeks after Helicobacter pylori eradication therapy end for eradication success control.
Percentage of invited individuals who return a Stool antigen test (SAT) sample.
Number of invited individuals who return a SAT sample divided by the number invited, multiplied by 100.
Time frame: Within 30 days after test kit distribution, according to site-specific procedures.
Percentage of eligible individuals who receive a study invitation
Number of eligible individuals who receive a study invitation divided by the number of eligible individuals identified for invitation, multiplied by 100.
Time frame: During the study recruitment period, up to 12 months.
Percentage of stool antigen test (SAT)-positive participants who start Helicobacter pylori Eradication Therapy
Number of SAT-positive participants who start eradication therapy divided by the number of SAT-positive participants, multiplied by 100.
Time frame: From positive SAT result through initiation of eradication therapy, up to 12 months
Helicobacter pylori eradication rate
Number of SAT-positive participants offered eradication therapy who have a negative post-treatment confirmatory test (stool antigen test or 13C-urea breath test), divided by the number of SAT-positive participants offered therapy, multiplied by 100.
Time frame: At least 4 weeks after completion of eradication therapy, up to 12 months
Participant-reported reasons for participation in or refusal of Helicobacter pylori testing
Participant-reported reasons for participation in or refusal of Helicobacter pylori testing, summarized by response category.
Time frame: At the screening participation decision.
Percentage of participants who take at least 90% of prescribed eradication therapy
Number of participants who take at least 90% of prescribed doses, divided by the number who start therapy, multiplied by 100.
Time frame: From initiation through completion of eradication therapy (10-14 days)
Percentage of referred participants who undergo upper gastrointestinal endoscopy
Number of participants referred for upper gastrointestinal endoscopy who undergo the procedure divided by the number of participants referred for upper gastrointestinal endoscopy, multiplied by 100.
Time frame: Through study completion, an average of 1 year
Percentage of participants meeting criteria for referral to upper gastrointestinal endoscopy
Number of participants meeting protocol-defined criteria for referral to upper gastrointestinal endoscopy divided by the number of participants assessed for the applicable referral criteria, multiplied by 100.
Time frame: At initial screening assessment
Percentage of returned Stool antigen test (SAT) samples not valid for testing
Number of returned SAT samples rejected as invalid divided by the total number returned, multiplied by 100.
Time frame: Through study completion, an average of 1 year
Reasons for invalid Stool Antigen Test (SAT) samples
Reasons returned SAT samples are considered invalid for testing, including late return and inappropriate sample collection, summarized by reason category.
Time frame: Through study completion, an average of 1 year
Percentage of Fecal immunochemical test (FIT)-positive participants who undergo follow-up colonoscopy
Number of FIT-positive participants who undergo colonoscopy divided by the number of FIT-positive participants, multiplied by 100.
Time frame: Through study completion, an average of 1 year
Colonoscopy findings among Fecal immunochemical test (FIT)-positive participants undergoing follow-up colonoscopy
Colonoscopy findings among FIT-positive participants who undergo follow-up colonoscopy, summarized by finding category.
Time frame: Through study completion, an average of 1 year
Helicobacter pylori positivity by Stool antigen test (SAT) among participants
Number of participants with a positive SAT divided by the number with a valid SAT result, multiplied by 100.
Time frame: Through study completion, an average of 1 year
Percentage of participants with a positive Fecal Immunochemical Test (FIT)
Number of participants with a positive FIT result divided by the number of participants with a valid FIT result, multiplied by 100.
Time frame: Through study completion, an average of 1 year
Percentage of invited individuals who return a Fecal Immunochemical Test (FIT) sample
Number of invited individuals who return a FIT sample divided by the number of invited individuals, multiplied by 100.
Time frame: Through study completion, an average of 1 year
Percentage of participants who complete post-treatment H. pylori eradication confirmation testing
Number of participants who complete post-treatment confirmatory testing divided by the number of participants eligible for post-treatment confirmatory testing, multiplied by 100.
Time frame: At least 4 weeks after completion of eradication therapy, up to 12 months
Reasons for non-completion of H. pylori eradication therapy
Participant-reported reasons for completing less than 90% of the prescribed eradication therapy, including self-reported adverse effects and other factors contributing to discontinuation.
Time frame: During eradication therapy (10-14 days).
Upper gastrointestinal endoscopic findings
Endoscopic findings among participants who undergo upper gastrointestinal endoscopy, summarized by finding category.
Time frame: Through study completion, an average of 1 year
Upper gastrointestinal histological findings
Histological findings among participants with biopsy specimens obtained during upper gastrointestinal endoscopy, summarized by finding category.
Time frame: Through study completion, an average of 1 year
No study locations are listed for this record.
Documents are hosted by the registry — open the source record to download them.
Plan to share: No — Individual participant data are not planned to be made generally available to other researchers. Data may be shared with authorized research partners only as permitted by the study protocol and applicable data governance framework, subject to participant consent and ethical approval where applicable, appropriate data-sharing agreements, and data protection requirements
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
Of 461 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 132. This study's planned 12 months is below that.
Counting every sponsor, half of 562 studies reached it within 53 months; a quarter within 28 and three quarters within 103.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Latvia